



EXECUTIVE OFFICE OF HEALTH AND HUMAN SERVICES
COMMONWEALTH OF MASSACHUSETTS
OFFICE OF MEDICAID
ONE ASHBURTON PLACE, BOSTON, MA 02108



MAURA T. HEALEY
GOVERNOR

KATHLEEN E. WALSH
SECRETARY

KIMBERLEY DRISCOLL
LIEUTENANT GOVERNOR

MIKE LEVINE
ASSISTANT SECRETARY
FOR MASSHEALTH

August 5, 2024

Chair Michael J. Rodrigues
Senate Committee on Ways and Means
State House, Room 212
Boston, MA 02133

Chair Aaron Michlewitz
House Committee on Ways and Means
State House, Room 243
Boston, MA 02133

Chair Cindy F. Friedman
Joint Committee on Health Care Financing
State House, Room 313
Boston, MA 02133

Chair John Lawn, Jr.
Joint Committee on Health Care Financing
State House, Room 236
Boston, MA 02133

Dear Chairs Rodrigues, Michlewitz, Friedman, and Lawn:

Chapter 28 of the Acts of 2023 line item 4000-0300 requires the Executive Office of Health and Human Services to submit a quarterly report including the projected total costs for the next fiscal year of pharmaceutical pipeline drugs identified by the executive office and expected to be made available for utilization within a 12-month period.

The Executive Office of Health and Human Services has identified 68 pipeline market entries from 73 manufacturers expected to be made available for utilization between April 1, 2024 and March 31, 2025. The estimated spend on the expected utilization of these products for all MassHealth members (including those enrolled with managed care) is approximately \$13.9M for the same time period. The prior quarterly report estimated a spend of \$24.8M based on the addition of 68 pipeline market entries from 78 manufacturers. Cell and gene therapies remain the largest driver of anticipated spend (approximately 70%). The decrease in spend from the previous report is due to the approval of two gene therapies.

Please contact Sarah Nordberg at Sarah.Nordberg@mass.gov should you have any questions about this report.

Sincerely,

Mike Levine
cc: Kathleen E. Walsh